pocketful logo light
pocketful logo light
Lincoln Pharmaceuticals Ltd logo

Lincoln Pharmaceuticals Ltd

NSE: LINCOLN BSE: 531633

₹705.20

(0.72%)

Wed, 27 May 2026, 04:13 pm

mtf coin illustrationMTF 5x

Lincoln Pharmaceuticals Share Price Live Chart

1 Day

(0.72%)

No Result Found

Summary

  • Market Cap

    1492.72

  • Net Profit

    82.35

  • P/B

    1.64

  • Sector P/E

    34.32

  • P/E

    13.42

  • EV/EBITDA

    8.73

  • Debt/Equity (Industry)

    0.26

  • Interest Cover (Industry)

    10.81

  • ROCE (Industry)

    16.40

  • RONW (Industry)

    14.39

  • ROE

    13.02

  • ROCE

    17.42

  • Debt/Equity

    0

  • EPS (TTM)

    43.85

  • Dividend Yield

    0.24

  • Book Value

    357.35

  • Interest Cover

    59.08

Analysis

all

thumbs up icon

Pros

  • Dividends per share have increased over the past 10 years.
  • Dividends paid are thoroughly covered by earnings (17x coverage).
  • Lincoln Pharmaceuticals's pays a higher dividend yield than the bottom 25% of dividend payers in India (0.76%).
  • Lincoln Pharmaceuticals's earnings growth is expected to exceed the low risk savings rate of 7.2%.
  • Lincoln Pharmaceuticals's earnings are expected to exceed the low risk growth rate next year.
thumbs up icon

Cons

  • Dividends per share have been volatile in the past 10 years (annual drop of over 20%).
  • Lincoln Pharmaceuticals's dividend is below the markets top 25% of dividend payers in India (3.08%).
  • Lincoln Pharmaceuticals's earnings are expected to grow by 15.9% yearly, however this is not considered high growth (20% yearly).
  • Lincoln Pharmaceuticals's earnings growth is positive but not above the India market average.
  • Lincoln Pharmaceuticals's revenue is expected to grow by 13.2% yearly, however this is not considered high growth (20% yearly).

Read More

Financials

Read More

Ratios

Read More

Shareholding

ShareholdersMAR 2026DEC 2025SEPT 2025JUN 2025MAR 2025
Promoters49.7849.7849.7849.7849.78
FII5.194.704.725.145.00
DII1.090.010.010.010.01
Public43.9445.5245.4945.0745.22
Government00000

Read More

Technical Analysis

RSI

69.37

MACD

32.23

50 DMA

631.70

200 DMA

554.45

Support and Resistance

TypeR3R2R1PPS1S2S3
Classic1017.27829.27737.53641.27549.53453.27265.27
Fibonacci829.27757.45713.08641.27569.45525.08453.27
Camarilla697.50680.27663.03641.27628.57611.33594.10

Pivots Level: Classic

R3

+376

1017.27

R2

+188

829.27

R1

+96.27

737.53

641.27
641.27
Pivot Point
LTP: 758.15

S1

-91.73

549.53

S2

-188

453.27

S3

-376

265.27

Moving Average

SMAEMA

Period

Value

  • 10-EMA

    718.07

  • 20-EMA

    691.64

  • 30-EMA

    672.77

  • 50-EMA

    645.74

  • 100-EMA

    606.57

  • 200-EMA

    583.23

Read More

Corporate Actions

Announcement DatePurposeActionEx Date
12 Feb 2026board-meetingsQuarterly Results
13 Nov 2025board-meetingsQuarterly Results, Half Yearly Results
29 Aug 2025agm
12 Aug 2025dividendFinal Dividend - Rs. - 1.812 Sept 2025
22 May 2025dividend₹1.80 Dividend /Share12 Sept 2025
02 Sept 2024agm
13 Aug 2024dividendDividend - Rs 1.80 Per Share14 Sept 2024
16 May 2024dividend₹1.80 Dividend /Share14 Sept 2024
26 Aug 2023agm
15 Aug 2023dividendAnnual General Meeting/Dividend - Rs 1.50 Per Share16 Sept 2023

Read More

Peer Comparison

Lincoln Pharmaceuticals Ltd logo

Lincoln Pharmaceuticals Ltd

Sun Pharmaceutical Industries Ltd logo

Sun Pharmaceutical Industries Ltd

Torrent Pharmaceuticals Ltd logo

Torrent Pharmaceuticals Ltd

Dr Reddys Laboratories Ltd logo

Dr Reddys Laboratories Ltd

Divis Laboratories Ltd logo

Divis Laboratories Ltd

Cipla Ltd logo

Cipla Ltd

Read More

Lincoln Pharmaceuticals Ltd About

Lincoln Pharmaceuticals is engaged in the business of manufacturing and trading of pharmaceutical products.

Industry

Pharmaceuticals - Indian - Formulations

Founded

1995

Headquarters

CEO

Kishorbhai M Shah

Employees

Contact

Website icon

Website

http://www.lincolnpharma.com

Email icon

Email

cs@lincolnpharma.com; investor@lincolnpharma.com

Phone icon

Phone

91-079-67778000

Location icon

Location

Lincoln House B/H Satyam Compe, Science City Road Sola, Ahmedabad, Gujarat, 380060

Read More

Lincoln Pharmaceuticals Ltd Company History

YearHistory
2014
  • Lincoln Pharmaceuticals Ltd has launched an Ultramodern State of Art plant for Injectable.
  • Company has commended the payment of Dividend of Rs. 0.60/- per equity share (@ 6%) of face value of Rs. 10/- each of the Company.
2015
  • The company has successfully launched a cough syrup called Namcold DX which contains Dextromethorphan Polistrirex.
2016
  • Lincoln Pharmaceuticals launches Vaginal Spray for FIRST TIME IN INDIA.
2020
  • Lincoln Pharma gets Gujarat food & drug regulator nod to manufacture COVID-19 drugs.
  • The company has received approval from the state regulator to manufacture varied dosages of HCQ tablets and HCQ sulfate tablets among others at Khatraj plant.
2021
  • The company received approval for the company's manufacturing facility from Australia's medicines and medical devices regulator.

Read More

Deals

Client NameDeal TypeOrder SideQTYAvg PriceDate
NK SECURITIES RESEARCH PRIVATE LIMITEDbulkSell208466707.9329 Apr 2026
QE SECURITIES LLPbulkBuy109936701.4629 Apr 2026
QE SECURITIES LLPbulkSell106989709.2829 Apr 2026
NK SECURITIES RESEARCH PRIVATE LIMITEDbulkBuy208466707.5129 Apr 2026
GREENX WEALTH MULTIHORIZONS OPPORTUNITY FUNDbulkBuy165255603.0712 Feb 2026
IRAGE BROKING SERVICES LLPbulkBuy92372599.3507 Aug 2025
NK SECURITIES RESEARCH PRIVATE LIMITEDbulkBuy275585599.4907 Aug 2025
IRAGE BROKING SERVICES LLPbulkBuy137847600.7407 Aug 2025
IRAGE BROKING SERVICES LLPbulkSell125529602.2507 Aug 2025
MUSIGMA SECURITIESbulkBuy160300604.9707 Aug 2025

Read More

Lincoln Pharmaceuticals Ltd News

Lincoln Pharma Board Meet Set for May 28, 2026

Lincoln Pharmaceuticals' board will meet on May 28, 2026 to consider audited standalone and consolidated financial results for Q4 and FY26, along with a possible dividend recommendation.

18 May 2026

companies

Lincoln Pharma Issues IEPF Share Transfer Notice

Lincoln Pharmaceuticals Ltd published a newspaper advertisement on May 08, 2026, notifying shareholders of equity share transfers to IEPF Authority for unclaimed dividends over seven consecutive years.

08 May 2026

companies

Lincoln Pharma Confirms Non-Large Corporate Status

Lincoln Pharmaceuticals Limited informs stock exchanges that it does not qualify as a Large Corporate under SEBI framework for FY 2026-27, submitting required disclosure as per regulatory circular.

16 Apr 2026

companies

Lincoln Pharma Files Q4FY26 SEBI Compliance Certificate

Lincoln Pharmaceuticals Limited submitted its quarterly confirmation certificate under SEBI Depositories Regulations for Q4FY26, confirming proper dematerialisation processes through registrar MUFG Intime India.

06 Apr 2026

companies

Lincoln Pharma Q3 FY26 Revenue Rises 13.5% to ₹166.32 Cr

Lincoln Pharmaceuticals reports strong Q3 FY26 performance with revenue growth of 13.5% and net profit surge of 37.7% to ₹28.60 crores, driven by domestic and export expansion.

23 Feb 2026

co actions results

Read More